Evaluating HPV vaccine coverage in young women with chronic diseases
Evaluation of Human Papillomavirus Vaccine Coverage in Girls and Young Women With Chronic Disease
This study is trying to see how many girls and young women with chronic diseases are getting the HPV vaccine compared to those without chronic conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 448 (estimated) |
| Ages | 11 Years to 20 Years |
| Sex | Female |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 2 sites (Paris and 1 other locations) |
| Trial ID | NCT06158802 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the vaccination coverage rate of the human papillomavirus (HPV) vaccine among girls and young women aged 11 to 20 with chronic diseases treated at the Necker-Enfants Malades Hospital. It compares this group to a control group of adolescents without chronic conditions. The study utilizes questionnaires to gather data on vaccination rates and factors influencing these rates. Given the higher risk of HPV-related complications in individuals with chronic conditions, understanding vaccination coverage is crucial for improving public health outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are girls and young women aged 11 to 20 with chronic conditions such as diabetes, cystic fibrosis, or heart disease, who are being treated at specified hospitals in France.
Not a fit: Patients who have contraindications to the HPV vaccine or do not meet the age and health criteria will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved vaccination strategies and increased HPV vaccination rates among vulnerable populations.
How similar studies have performed: Other studies have indicated low vaccination coverage rates among similar populations, highlighting the need for targeted interventions, making this approach both relevant and necessary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Information and non-opposition of major patients and holders of parental authority of minor patients and minor patients
* Girls and young women aged 11 to 20
* To be followed at the Necker-Enfants Malades Hospital ("chronic condition" group)
* To be followed at the Specialized Medical Center for Children and Adolescents ("control" group)
* Have a chronic condition ("chronic condition" group) :
* Diabetes type 1
* Metabolic diseases
* Patients followed in immuno-hematology
* Cystic Fibrosis
* Sickle
* Kidney transplant
* Heart Disease
* Inflammatory bowel diseases
* Rare anorectal and pelvic anomalies
* Live in France
* Comprehension of the French language (oral and written)
Exclusion Criteria:
* Have a contraindication to the HPV vaccine - Gardasil 9 (Vidal Hoptimal, 2018)
* Have a contraindication to the HPV vaccine - Gardasil (Vidal Hopitmal, 2018)
* Have a contraindication to HPV vaccine - Cervarix (Vidal Hoptimal, 2018)
Where this trial is running
Paris and 1 other locations
- Centre Médical Spécialisé de l'Enfant et de l'Adolescent (CMSEA) — Paris, France (Recruiting)
- Hôpital Necker-Enfants Malades — Paris, France (Recruiting)
Study contacts
- Principal investigator: Sabrina DA COSTA, MD — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Sabrina DA COSTA, MD
- Email: sabrina.dacosta@aphp.fr
- Phone: 1 44 49 48 04
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.